"Welcome to Volume 19 of Drugline ENTECAVIR (Baraclude, Bristol-Myers"
Friday 5th August 2005 Welcome to Volume 19 of Drugline ENTECAVIR (Baraclude, Bristol-Myers Squibb) Entecavir is a nucleoside analogue with selective activity against the hepatitis B virus (HBV). Entecavir inhibits DNA synthesis in HBV infected cells, reducing viral load and disease burden in infected patients. In animal studies, long-term administration of the drug was shown to reduce viral load to undetectable levels for 3 to 5 years. Entecavir is specifically indicated for the treatment of chronic HBV infection in adults with evidence of active viral replication and either evidence of persistent elevation in serum aminotransferase (ALT or AST) or histologically active disease. The recommended dose in adults and adolescents over the age of 16 is 0.5 mg daily on an empty stomach. The dose is increased to 1mg daily for patients with a history of hepatis B viremia receiving lamivudine or with known lamivudine resistant virus mutations. For patients with renal impairment (creatinine clearance < 50 mL/min) dosage adjustment may be necessary. Baraclude is supplied in 0.5 mg and 1 mg tablets and a solution of 0.5 mg per 10 ml. Entecavir was approved by the FDA in March. It is anticipated that Entecavir will be available in Australia next year with a view to being listed on the PBS in 2007. Article researched and written by: Joe Gelb, HPS Pharmacies, Partner / Clinical Publicist. Your feedback on what you'd like to see and what you find interesting will be integral to the production of this bulletin. Please email me direct, firstname.lastname@example.org. I look forward to your comments. Kind regards Jody Martin National Manager, Marketing & Communications HPS Pharmacies, 29 Alexander Avenue, Ashford SA 5035 t 08 8375 3617 f 08 8371 5812 e email@example.com www.hpspharmacies.com.au To unsubscribe from future announcements about HPS Pharmacies' services, click here